Lv51
1250 积分 2022-08-16 加入
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer
2小时前
已完结
Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options
2个月前
已完结
Recommendations for the Use of White Blood Cell Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
2个月前
已完结
Claudin 18.2 as a novel therapeutic target
3个月前
已完结
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
3个月前
已完结
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
3个月前
已完结
Optimizing CAR T cell therapy for solid tumours: a clinical perspective
3个月前
已完结
Beyond the blood: expanding CAR T cell therapy to solid tumors
3个月前
已完结
Proceedings
4个月前
已完结
慢性乙型肝炎防治指南
4个月前
已完结
皖公网安备34019202002308
